Literature DB >> 19762399

Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.

M Petri1, S Singh, H Tesfasyone, R Dedrick, K Fry, Pg Lal, G Williams, Jw Bauer, Pk Gregersen, Tw Behrens, Ec Baechler.   

Abstract

Cross-sectional studies of patients with systemic lupus erythematosus (SLE) have demonstrated an association between activation of type I interferon (IFN) pathway and disease activity. This study examined longitudinal changes in IFN-regulated gene expression in peripheral blood using microarrays. A cross-section of 66 patients from the Autoimmune Biomarkers Collaborative Network SLE archive was evaluated. We also examined paired samples from a 15 patient subset collected during a period of low disease activity (Baseline) and at a subsequent flare event, and baseline scores of 29 patients who maintained low disease activity. IFN response (IFNr) scores were calculated from three IFN-regulated genes. Overall, higher IFNr scores were associated with increased disease activity. However, IFNr scores were not significantly different between the paired Baseline and Flare samples. An extended longitudinal analysis in 11 patients indicated little change in IFNr scores over time, even during dynamic disease activity. In patients with low disease activity, IFNr scores were not different between patients who experienced a subsequent flare and those who maintained low disease activity. In summary, although higher IFNr scores were associated with greater disease activity, IFNr scores of individual patients did not correlate with changes in disease severity or flare risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762399      PMCID: PMC4752166          DOI: 10.1177/0961203309105529

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  42 in total

1.  Hopkins Lupus Cohort. 1999 update.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2000-05       Impact factor: 2.670

2.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Authors:  Xuebing Feng; Hui Wu; Jennifer M Grossman; Punchong Hanvivadhanakul; John D FitzGerald; Grace S Park; Xin Dong; Weiling Chen; Michelle H Kim; Haoling H Weng; Daniel E Furst; Alan Gorn; Maureen McMahon; Mihaela Taylor; Ernest Brahn; Bevra H Hahn; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2006-09

3.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

Authors:  D D Gladman; M B Urowitz; A Kagal; D Hallett
Journal:  J Rheumatol       Date:  2000-02       Impact factor: 4.666

6.  A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.

Authors:  Robert R Graham; Sergey V Kozyrev; Emily C Baechler; M V Prasad Linga Reddy; Robert M Plenge; Jason W Bauer; Ward A Ortmann; Thearith Koeuth; Ma Francisca González Escribano; Bernardo Pons-Estel; Michelle Petri; Mark Daly; Peter K Gregersen; Javier Martín; David Altshuler; Timothy W Behrens; Marta E Alarcón-Riquelme
Journal:  Nat Genet       Date:  2006-04-16       Impact factor: 38.330

Review 7.  The emerging role of interferon in human systemic lupus erythematosus.

Authors:  Emily C Baechler; Peter K Gregersen; Timothy W Behrens
Journal:  Curr Opin Immunol       Date:  2004-12       Impact factor: 7.486

8.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

9.  Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus.

Authors:  M Nikpour; A A Dempsey; M B Urowitz; D D Gladman; D A Barnes
Journal:  Ann Rheum Dis       Date:  2007-12-06       Impact factor: 19.103

Review 10.  Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy.

Authors:  K N Schmidt; W Ouyang
Journal:  Lupus       Date:  2004       Impact factor: 2.911

View more
  85 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.

Authors:  Sandra Agik; Beverly S Franek; Akaash A Kumar; Marissa Kumabe; Tammy O Utset; Rachel A Mikolaitis; Meenakshi Jolly; Timothy B Niewold
Journal:  J Rheumatol       Date:  2011-11-01       Impact factor: 4.666

3.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

Review 4.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

5.  Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure.

Authors:  Chao Dai; Hongyang Wang; Sun-Sang J Sung; Rahul Sharma; Carol Kannapell; Wei Han; Qian Wang; Anne Davidson; Felicia Gaskin; Shu Man Fu
Journal:  Clin Immunol       Date:  2014-06-27       Impact factor: 3.969

6.  Endotoxin tolerance in monocytes can be mitigated by α2-interferon.

Authors:  Lihua Shi; Li Song; Kelly Maurer; James Sharp; Zhe Zhang; Kathleen E Sullivan
Journal:  J Leukoc Biol       Date:  2015-07-23       Impact factor: 4.962

Review 7.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 8.  Assessing the human immune system through blood transcriptomics.

Authors:  Damien Chaussabel; Virginia Pascual; Jacques Banchereau
Journal:  BMC Biol       Date:  2010-07-01       Impact factor: 7.431

9.  A new tool for detection of type I interferon activation in systemic lupus erythematosus.

Authors:  Kyriakos A Kirou; George D Kalliolias
Journal:  Arthritis Res Ther       Date:  2010-08-26       Impact factor: 5.156

Review 10.  Interferon alpha in systemic lupus erythematosus.

Authors:  Timothy B Niewold; Daniel N Clark; Rafah Salloum; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2010-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.